Off-Label Regulation Is One Theme Of House Antidepressant Hearing
Executive Summary
The congressional investigation into antidepressant safety could renew interest in how off-label promotion is regulated in the U.S
You may also be interested in...
FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach
FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach
Pediatric Exclusivity Incentive May Encourage Sloppy Trials, FDA Says
The quality of pediatric research on antidepressants may have been affected by the need for manufacturers to complete trials in time to receive exclusivity extensions, FDA Office of Drug Evaluation I Acting Director Robert Temple, MD, suggested during the Sept. 13-14 advisory committee review of antidepressant safety